Literature DB >> 10796224

Amnioinfusion for preterm rupture of membranes.

G J Hofmeyr1.   

Abstract

BACKGROUND: Preterm rupture of membranes places a fetus at risk of cord compression and amnionitis. Amnioinfusion aims to prevent or relieve umbilical cord compression by infusing a solution into the uterine cavity.
OBJECTIVES: The objective of this review was to assess the effects of amnioinfusion for preterm rupture of membranes on maternal and perinatal outcomes. SEARCH STRATEGY: The Cochrane Pregnancy and Childbirth Group trials register and the Cochrane Controlled Trials Register were searched. SELECTION CRITERIA: Randomised trials of amnioinfusion compared to no amnioinfusion in women with preterm rupture of membranes. DATA COLLECTION AND ANALYSIS: Eligibility and trial quality were assessed by the reviewer. MAIN
RESULTS: One trial of 66 women was included. It had some methodological flaws. No significant differences between amnioinfusion and no amnioinfusion were detected for caesarean section (relative risk 0.32, 95% confidence interval 0.07 to 1.40); low Apgar scores (relative risk 0.28, 95% confidence interval 0.03 to 2.33) or neonatal death (relative risk 0.55, 95% confidence interval 0.05 to 5.77). In the amnioinfusion group, the number of severe fetal heart rate decelerations per hour during the first stage of labour were reduced (weighted mean difference -1.20, 95% confidence interval -1.83 to -0.57). These outcomes are consistent with those found in the Cochrane review on amnioinfusion for cord compression. REVIEWER'S
CONCLUSIONS: There is not enough evidence concerning the use of amnioinfusion for preterm rupture of membranes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10796224     DOI: 10.1002/14651858.CD000942

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  1 in total

Review 1.  Planned home versus hospital care for preterm prelabour rupture of the membranes (PPROM) prior to 37 weeks' gestation.

Authors:  Ghada Abou El Senoun; Therese Dowswell; Hatem A Mousa
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.